India’s Active Pharmaceutical Ingredient (API) sector, currently valued at $15-16 billion, is poised for steady expansion. A new report from CareEdge Ratings forecasts a compound annual growth rate (CAGR) of 5-7% for fiscal years 2027 and 2028. This growth trajectory reflects a combination of supportive government policies and shifting market dynamics.
The report highlights a structural shift towards high-potency and complex APIs, driven by rising domestic demand and deeper market penetration in regulated and emerging economies. Indian pharma companies are strategically moving from basic to sophisticated APIs to counter price erosion, boost profit margins, and retain customers.
Despite ongoing reliance on China for key raw materials, progress is evident through government-backed initiatives like the Production-Linked Incentive (PLI) scheme and Bulk Drug Parks. Over 30 projects have been completed, with several firms launching new capacities under these programs. Rating agency officials note that while full impacts will take time, the momentum is building.
A robust pipeline of advanced APIs is in development, signaling India’s gradual ascent in the global value chain. Commercialization of these projects is expected in the coming years, though significant growth may materialize in 2-4 years as production scales up.
Pritesh Rathi, Assistant Director at CareEdge Ratings, attributes long-term drivers to an aging population, improved healthcare access, rising insurance coverage, chronic disease prevalence, reduced monopolies, and expansion into emerging markets. Government-supported Bulk Drug Parks are set to define the next investment phase, with nearly 80% of ongoing projects linked to this initiative.
Major developments include large-scale facilities in Andhra Pradesh, Himachal Pradesh, and Gujarat, costing between 20-40 billion rupees. These aim to fortify domestic API production, reduce import dependence, and enhance cost efficiencies across the sector. As India strengthens its pharmaceutical backbone, the API market is on track for sustainable growth amid global challenges.